(MENAFN- EIN Presswire)
Defined radio Waves Attenuate a Head-Twitch Response in Mice Elicited by Dimethoxy-4-iodoamphetamine (DOI) - Journal of Electromagnetic Biology and Medicine
These preliminary results are the first independent demonstration using an established (gold standard) animal model in psychedelics, suggesting applicability of ulRFE in a clinical setting.” - Chris E. Rivera, President, CEO & ChairmanBELLEVUE, WA, UNITED STATES, October 24, 2024 /EINPresswire / -- EMulate Therapeutics, Inc. Announces the Acceptance for Publication of Its Paper Titled“Defined
Radio Wave Frequencies Attenuate the Head-Twitch Response in Mice Elicited by (±)-2,5-Dimethoxy-4-iodoamphetamine (DOI)” in the Journal of Electromagnetic Biology and Medicine
Hyperlink To Publication
EMulate Therapeutics, Inc. (EMTx) is proud to announce the acceptance of a collaborative publication with Mercer University's Clinton Canal, Ph.D. and Mary Vu, Ph.D. (candidate). This publication represents the first application of a psychedelic ulRFE (ultra-low Radio Frequency Energy) signal in an animal model.
“This publication with Dr. Canal represents a potentially new market space in multiple mental-health applications,“ stated Mr. Chris Rivera, Chairman and CEO of EMTx.“These preliminary results are the first independent demonstration using an established (gold standard) animal model in psychedelics, suggesting applicability of ulRFE in a clinical setting.” Our ulRFE technology may offer effective anxiety and depression treatment alternatives, with little or no side effects.
“These results demonstrate the specific ability of our ulRFE (ultra-low Radio Frequency Energy) signals to affect known targets of psychedelic drugs, without the need of the actual drug(s),” stated Xavier Figueroa, PhD, senior vice-president at EMTx.“Further testing and refinement in a clinical setting will allow for validation and approval via the FDA which is begin planned for early 2025.”
About EMulate Therapeutics, Inc.
EMulate Therapeutics is a clinical stage company utilizing its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to provide safe and effective therapeutic benefits specifically targeted at patients' underlying conditions. The company has generated encouraging human clinical results from patients afflicted with glioblastoma and diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), and is preparing for pivotal (phase III) studies in each indication using its proprietary A1A treatment signal emulating the mechanism of action of paclitaxel, a well-known and characterized chemotherapy agent. The company has submitted an application to the FDA for approval to treat U.S. patients diagnosed with DMG via the humanitarian device exemption (HDE) regulatory pathway and to commercialize this treatment product. It has also generated encouraging preclinical studies in pain management and mental health models and is preparing for initial human clinical trials in each area. In addition, positive data have been generated independently in animal health (positive cancer results in over 20 different solid tumor types in canines (pets)), as well as in bio-agriculture models. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial stage consumer wellness-wearable technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.
About our ulRFE Device
EMTx has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, portable investigational medical device that uses low to ultra-low level (DC-22kHz) frequencies to create and deliver specific electromagnetic fields that produce specific biological effects, including, e.g., increasing tubulin polymerization in numerous cancer models, emulating the effects of psychedelic drugs in mental health models and reducing pain sensations, among others. The system emits a low power magnetic field (< 100 mG) that can be applied locally or globally, depending on the type of therapeutic effect sought. The EMTX signals are stored as WAV files on the device and emitted via a cable to the attached antenna unit.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains“forward-looking statements.” Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as“believe,”“may,”“will,”“estimate,”“continue,”“anticipate,”“intend,”“expect,”“could,”“should,”“would,”“plan,”“project,”“forecast,” and“potential,” the negatives thereof or similar expressions. Forward-looking statements speak only as of the date made, are based on various underlying assumptions and current expectations about the future and are not guarantees of future performance. While we believe these assumptions and expectations are reasonable, are made in good faith and have a reasonable basis, assumed facts or bases almost always vary from actual results, and the differences between assumed facts or expectations and actual results can be material, depending on the circumstances. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates, or to regard them as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved.
Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.
Company Contact:
Kyle Kingma - ...
Kyle Kingma
EMulate Therapeutics, Inc.
+1 206-330-4007
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN24102024003118003196ID1108815501
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.